Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13C-oxalate (specifically [13C2]oxalate or carbon-13 labeled oxalate) is a stable isotope-labeled form of oxalate used as a diagnostic tracer to measure gastrointestinal oxalate absorption. Administered orally as sodium [13C2]oxalate or [13C2]oxalic acid, it is utilized in the standardized [13C2]oxalate absorption test to differentiate between metabolic (endogenous) and enteric/dietary (exogenous) hyperoxaluria. Because carbon-13 is a non-radioactive, stable isotope, the test is safe for repeated use in both adult and pediatric populations, including patients with calcium oxalate kidney stones, primary or secondary hyperoxaluria, and Crohn's disease. Following oral ingestion, the absorption rate is calculated based on the recovery of labeled oxalate in the urine (typically measured via gas chromatography-mass spectrometry, GC-MS, or LC-MS/MS) or the appearance of 13CO2 in breath samples as an indicator of intraluminal oxalate degradation by the gut microbiome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 13C-oxalate.